KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Receivables (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 13 years of Change in Receivables data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 159.81% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $20.8 million, up 1011.48%, while the annual FY2025 figure was $20.8 million, 1011.48% up from the prior year.
  • Change in Receivables reached $3.7 million in Q4 2025 per ACAD's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $35.2 million in Q4 2023 and bottomed at -$18.8 million in Q3 2023.
  • Average Change in Receivables over 5 years is $3.7 million, with a median of $3.6 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: crashed 363.23% in 2021, then surged 1750.72% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $17.2 million in 2021, then tumbled by 50.3% to $8.5 million in 2022, then soared by 312.49% to $35.2 million in 2023, then crashed by 117.59% to -$6.2 million in 2024, then soared by 159.81% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $3.7 million in Q4 2025, $8.3 million in Q3 2025, and $1.8 million in Q2 2025.